Cerebral Arrays- Measurement of analytes associated with nervous system dysfunction
Neurological disorders can affect the central, somatic and autonomic nervous system. At the molecular level, many analytes have been found to have involvement in the pathophysiology of this complex interacting system.
Proteins such as NSE are considered to be neurochemical markers of brain damage and appear to have predictive value for outcome after acute stroke. BDNF and GFAP have been linked to Alzheimer’s disease and MS. Inflammatory processes have increasingly been shown to be implicated in the pathogenesis of cerebrovascular disease and CRP has been identified as a predictor of future stroke risk.
Cerebral Array I Analytes
Cerebral Array II Analytes
Key Benefits of Randox Cerebral Arrays
- Rapid turnaround time
- Measures up to 5 cerebral biomarkers simultaneously
- Human serum, plasma and cerebrospinal fluid (CSF) samples
- Small sample volume: 35-100μl
- Applicable to both fully automated and semi-automated evidence analysers